Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Q Biomed Extends EOA with Washington U | Contract Pharma

What are you searching for?

Sign in
Breaking News

Q Biomed Extends EOA with Washington U

Allows for more extensive evaluation of GDF15 as a novel biomarker for glaucoma and companion diagnostic to MAN-01

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Q BioMed Inc. is extending its option agreement with Washington University in St. Louis, granting the exclusive right to license its technology. Q BioMed will continue to evaluate the feasibility and usability of GDF15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma. 

The agreement allows for more extensive evaluation on the feasibility and usability of GDF15 as a novel biomarker for glaucoma and companion diagnostic to Q BioMed’s exclusively licensed technology, MAN-01.

The clinical study will examine whether GDF-15 levels correlate with glaucoma severity and with adequate therapeutic response in patients undergoing glaucoma surgery. A primary goal of glaucoma surgeries is reducing IOP, as elevated IOP contributes to RGC death and vision loss. It will also record IOP measured before surgery and at the follow-up. IOP measurement is done at each visit as part of usual care of the patient. These independent studies will provide valuable insights regarding the role of GDF-15 that can inform future clinical studies.

Denis Corin, Q BioMed’s chief executive officer said, “We are very pleased to be taking this project one step further.  We believe that Q BioMed is uniquely positioned to address the marketable demand for novel, breakthrough, precision medicine tools to treat glaucoma.  This GDF-15 diagnostic, combined with our MAN-01 drug to treat glaucoma, will be a powerful combination: improving the decision-making tools for clinicians, while making a positive impact on the health of glaucoma patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics